BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 38577721)

  • 1. Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
    Budak B; Tükel EY; Turanlı B; Kiraz Y
    Ann Hematol; 2024 Jun; ():. PubMed ID: 38836918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.
    Ganguly S; Sasi A; Pushpam D; Bakhshi S
    Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of BCR::ABL1 in laminin adhesion of Philadelphia chromosome-positive  acute lymphoblastic leukemia through upregulation of integrin α6.
    Takahashi K; Nguyen TTT; Watanabe A; Sato H; Saito K; Tamai M; Harama D; Kasai S; Akahane K; Goi K; Kagami K; Abe M; Komatsu C; Maeda Y; Sugita K; Inukai T
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2034. PubMed ID: 38577721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
    Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
    Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cell surface-expressed proteochondroitin sulfate of pre-B Nalm-6 cells and its possible role in laminin adhesion.
    Blase L; Merling A; Engelmann S; Möller P; Schwartz-Albiez R
    Leukemia; 1996 Jun; 10(6):1000-11. PubMed ID: 8667635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Piccaluga PP; Paolini S; Martinelli G
    Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
    Nguyen TTT; Tamai M; Harama D; Kagami K; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
    Int J Hematol; 2022 Oct; 116(4):534-543. PubMed ID: 35524023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin-Mediated Adhesion and Chemoresistance of Acute Lymphoblastic Leukemia Cells Residing in the Bone Marrow or the Central Nervous System.
    Scharff BFSS; Modvig S; Marquart HV; Christensen C
    Front Oncol; 2020; 10():775. PubMed ID: 32528884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of MEF2D fusion in human B-cell precursor acute lymphoblastic leukemia cell lines.
    Akahane K; Yasuda T; Tsuzuki S; Hayakawa F; Kiyokawa N; Somazu S; Watanabe A; Kagami K; Abe M; Harama D; Goi K; Kawazu M; Kojima S; Imamura T; Goto H; Iwamoto S; Minegishi M; Abe M; Hojo H; Inaba T; Mano H; Sugita K; Inukai T
    Hematol Oncol; 2020 Oct; 38(4):614-617. PubMed ID: 32515032
    [No Abstract]   [Full Text] [Related]  

  • 11. Response and Resistance to BCR-ABL1-Targeted Therapies.
    Braun TP; Eide CA; Druker BJ
    Cancer Cell; 2020 Apr; 37(4):530-542. PubMed ID: 32289275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.
    Gang EJ; Kim HN; Hsieh YT; Ruan Y; Ogana HA; Lee S; Pham J; Geng H; Park E; Klemm L; Willman CL; Carroll WL; Mittelman SD; Orgel E; Oberley MJ; Parekh C; Abdel-Azim H; Bhojwani D; Wayne AS; De Arcangelis A; Georges-Labouesse E; Wayner E; Bonig H; Minasyan A; Ten Hoeve J; Graeber TG; Müschen M; Heisterkamp N; Kim YM
    Blood; 2020 Jul; 136(2):210-223. PubMed ID: 32219444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive clinical study of integrins in acute lymphoblastic leukemia indicates a role of α6/CD49f in persistent minimal residual disease and α5 in the colonization of cerebrospinal fluid.
    Shah Scharff BFS; Modvig S; Thastrup M; Levinsen M; Degn M; Ryder LP; Schmiegelow K; Christensen C; Marquart HV
    Leuk Lymphoma; 2020 Jul; 61(7):1714-1718. PubMed ID: 32107949
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.